Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference

Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will present a company overview at the H.C. Wainwright & Co. Global Life Sciences Conference on March 9, 2021. A pre-recorded presentation will be accessible starting at 7:00 am ET. The presentation will be available on-demand on Curis's website under 'Events & Presentations' for about 90 days. Curis specializes in cancer therapeutics, with ongoing trials for treatments targeting various cancers, including non-Hodgkin's lymphoma and acute myeloid leukemia.

LEXINGTON, Mass., March 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the H.C. Wainwright & Co. Global Life Sciences Conference. A pre-recorded presentation will be available for on-demand viewing beginning at 7:00 am ET on Tuesday, March 9, 2021.

A webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. A replay of the webcast will be available on the Curis website for approximately 90 days following the event.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination with BTK inhibitor, ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-to-present-at-hc-wainwright--co-global-life-sciences-conference-301238362.html

SOURCE Curis, Inc.

FAQ

When will Curis present at the H.C. Wainwright & Co. Global Life Sciences Conference?

Curis will present on March 9, 2021, starting at 7:00 am ET.

What is the stock symbol for Curis?

The stock symbol for Curis is CRIS.

How can I view the Curis presentation?

The presentation can be viewed on Curis's website under 'Events & Presentations'.

What ongoing trials is Curis currently involved in?

Curis is conducting Phase 1 trials for CA-4948 in non-Hodgkin's lymphoma and acute myeloid leukemia.

What is CA-4948 being tested for?

CA-4948 is being tested as a monotherapy and in combination with ibrutinib for cancer treatment.